PH12021551475A1 - Heterodimeric proteins for modulating gamma delta t cells - Google Patents

Heterodimeric proteins for modulating gamma delta t cells

Info

Publication number
PH12021551475A1
PH12021551475A1 PH1/2021/551475A PH12021551475A PH12021551475A1 PH 12021551475 A1 PH12021551475 A1 PH 12021551475A1 PH 12021551475 A PH12021551475 A PH 12021551475A PH 12021551475 A1 PH12021551475 A1 PH 12021551475A1
Authority
PH
Philippines
Prior art keywords
cells
heterodimeric proteins
gamma delta
modulating gamma
modulating
Prior art date
Application number
PH1/2021/551475A
Other languages
English (en)
Inventor
Silva Suresh De
George Fromm
Taylor Schreiber
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of PH12021551475A1 publication Critical patent/PH12021551475A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PH1/2021/551475A 2019-01-07 2020-01-07 Heterodimeric proteins for modulating gamma delta t cells PH12021551475A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962789344P 2019-01-07 2019-01-07
US201962876346P 2019-07-19 2019-07-19
US201962941176P 2019-11-27 2019-11-27
PCT/US2020/012589 WO2020146393A1 (en) 2019-01-07 2020-01-07 Heterodimeric proteins for modulating gamma delta t cells

Publications (1)

Publication Number Publication Date
PH12021551475A1 true PH12021551475A1 (en) 2022-05-02

Family

ID=71521410

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/551475A PH12021551475A1 (en) 2019-01-07 2020-01-07 Heterodimeric proteins for modulating gamma delta t cells

Country Status (13)

Country Link
US (4) US11098093B2 (cg-RX-API-DMAC7.html)
EP (1) EP3902557A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022516964A (cg-RX-API-DMAC7.html)
KR (1) KR20210113244A (cg-RX-API-DMAC7.html)
CN (1) CN113329759A (cg-RX-API-DMAC7.html)
AU (1) AU2020205965A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021013193A2 (cg-RX-API-DMAC7.html)
CA (1) CA3125474A1 (cg-RX-API-DMAC7.html)
IL (1) IL284658A (cg-RX-API-DMAC7.html)
MX (1) MX2021008022A (cg-RX-API-DMAC7.html)
PH (1) PH12021551475A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106895UA (cg-RX-API-DMAC7.html)
WO (1) WO2020146393A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566650A (zh) 2018-06-21 2021-03-26 沙塔克实验室有限公司 异二聚体蛋白及其用途
BR112021013193A2 (pt) * 2019-01-07 2021-09-28 Shattuck Labs, Inc. Proteínas heterodiméricas para modulação de células t gama delta
WO2022093310A1 (en) * 2020-10-26 2022-05-05 Shattuck Labs, Inc. Homodimeric and heterodimeric proteins comprising butyrophilin
EP4247409A4 (en) * 2020-11-19 2024-11-13 Shattuck Labs, Inc. Methods of identifying gamma delta t cell-modulating agents
US20240076346A1 (en) * 2021-01-13 2024-03-07 Kahr Medical Ltd. Type i membrane proteins heterodimers and methods of use thereof
US20240082306A1 (en) * 2021-02-03 2024-03-14 Bioheng Therapeutics Limited Novel chimeric antigen receptor and use thereof
JP2024511992A (ja) * 2021-03-16 2024-03-18 シャタック ラボ,インコーポレイテッド ガンマデルタt細胞刺激
WO2023102617A1 (en) * 2021-12-09 2023-06-15 The University Of Melbourne Modified butyrophilin and butyrophilin complexes
WO2023154812A1 (en) * 2022-02-09 2023-08-17 Shattuck Labs, Inc. Multispecific heterodimeric proteins
WO2024006907A2 (en) * 2022-06-29 2024-01-04 Shattuck Labs, Inc. B7h3-targeted gamma delta t cell modulation
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024191989A1 (en) * 2023-03-14 2024-09-19 Shattuck Labs, Inc. Treatment of b cell-mediated diseases by activating cd20-targeted gamma delta t cells

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264360A1 (en) 2002-04-12 2006-11-23 Yale University Office Of Cooperstive Research Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4
US20040053307A1 (en) 2002-06-17 2004-03-18 Wyeth Inhibition of T cell activation by butyrophilin 4 and B7-L1
AU2004242846A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
EP1702622A1 (en) 2005-03-18 2006-09-20 CONARIS research institute AG Soluble BTNL2 protein useful to inhibit inflammatory disorders
DK1999154T3 (da) * 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2008154516A2 (en) 2007-06-11 2008-12-18 The Board Of Regents, The Universtity Ot Texas System Btnl2 fusion protein for t-cell activity modulation
GB0717101D0 (en) 2007-09-03 2007-10-10 Cambridge Entpr Ltd Tumour marker
EP3663318A1 (en) * 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2011127418A1 (en) 2010-04-09 2011-10-13 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
WO2011133886A2 (en) * 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
IN2014CN03887A (cg-RX-API-DMAC7.html) * 2011-10-27 2015-10-16 Genmab As
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
HUE037186T2 (hu) 2011-12-28 2018-08-28 Immunoqure Ag Eljárás humán antitestek izolálására
US20150166630A1 (en) 2012-07-19 2015-06-18 Amgen Inc. Btnl3 proteins, nucleic acids, and antibodies and uses thereof
EP2941438A1 (en) 2013-01-01 2015-11-11 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
GB201300049D0 (en) 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
GB201300052D0 (en) 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-suppressive dendritic cells
CN110724193B (zh) 2013-07-03 2023-05-05 因美诺克股份公司 人单克隆抗il-32抗体、多核苷酸、载体、宿主细胞、制备方法、组合物及应用
WO2015001047A1 (en) 2013-07-03 2015-01-08 Immunoqure Ag Method of providing anti-human cytokine antibodies for pharmaceutical use
CA2917112C (en) 2013-07-03 2022-07-05 Immunoqure Ag Human anti-ifn-alpha antibodies
US20160376364A1 (en) 2013-11-29 2016-12-29 Csl Limited Method of treating cancer
EP3087099A4 (en) * 2013-12-23 2017-07-19 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
CN106999584A (zh) 2014-11-25 2017-08-01 阿尔伯特爱因斯坦医学院公司 Btnl9和ermap作为用于免疫疗法的新的免疫系统抑制剂
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
US20180147257A1 (en) 2015-05-22 2018-05-31 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
SG10201913573UA (en) * 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
CN108473958A (zh) 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
KR102803158B1 (ko) 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
GB201521389D0 (en) * 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
EP3436475A1 (en) 2016-03-29 2019-02-06 STCube & Co., Inc. Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
WO2018082590A1 (zh) * 2016-11-02 2018-05-11 北京蛋白质组研究中心 肿瘤免疫治疗靶标及其应用
WO2018201130A1 (en) 2017-04-28 2018-11-01 The Brigham And Women's Hospital, Inc. Targeting gamma-delta t cells in obesity and cachexia
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー., インコーポレイテッド Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
EP4467146A3 (en) 2017-09-15 2025-05-07 King's College London Compositions and methods for enhancing gamma delta t cells in the gut
KR102764182B1 (ko) 2017-09-21 2025-02-07 임체크 테라퓨틱스 Btn2에 대해 특이성을 갖는 항체 및 이의 용도
BR112021013193A2 (pt) * 2019-01-07 2021-09-28 Shattuck Labs, Inc. Proteínas heterodiméricas para modulação de células t gama delta

Also Published As

Publication number Publication date
IL284658A (en) 2021-08-31
US11098093B2 (en) 2021-08-24
US20200308238A1 (en) 2020-10-01
EP3902557A4 (en) 2023-06-07
US20220025000A1 (en) 2022-01-27
MX2021008022A (es) 2021-08-05
US11643447B2 (en) 2023-05-09
WO2020146393A1 (en) 2020-07-16
AU2020205965A1 (en) 2021-07-01
SG11202106895UA (en) 2021-07-29
CN113329759A (zh) 2021-08-31
EP3902557A1 (en) 2021-11-03
KR20210113244A (ko) 2021-09-15
US20230020258A1 (en) 2023-01-19
BR112021013193A2 (pt) 2021-09-28
JP2022516964A (ja) 2022-03-03
US20200216505A1 (en) 2020-07-09
US10988517B2 (en) 2021-04-27
CA3125474A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
ZA202308519B (en) Anti-vegf protein compositions and methods for producing the same
MX2021008022A (es) Proteínas heterodiméricas para modular células t gamma delta.
EP4578507A3 (en) Compositions and methods for t cell engineering
PH12022550892A1 (en) Bicyclic heterocycles as fgfr inhibitors
EP4249067A3 (en) Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
MX2020010369A (es) Particulas implantables y metodos relacionados.
WO2018234793A3 (en) Antibodies
MY203971A (en) Anti-lag-3 antibodies and compositions
WO2018170150A3 (en) Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
MX2021015761A (es) Polipeptidos.
MX2021001524A (es) Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso.
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
MX2018011162A (es) Metodos de purificacion de colageno 7.
AU2020258568A8 (en) CD73 inhibitors
MX2022000425A (es) Metodos y composiciones que comprenden un nivel reducido de proteinas de celulas hospedadoras.
MX2021005245A (es) Composiciones de oligosacaridos y metodos de uso de las mismas.
WO2020205626A8 (en) Modulators of cell surface protein interactions and methods and compositions related to same
MX2024005649A (es) Proteinas quimericas basadas en sirp1a y cd40l.
PH12021552133A1 (en) Aromatic derivatives, preparation methods, and medical uses thereof
ZA202401405B (en) Compositions and methods for anti-pacap antibodies